Lastly, the subjects with IBD included in this study were receiving immune suppressing medications as part of their treatment, which may have had a disproportional effect on IL-6 production, thereby mitigating any potential rise in this biomarker. The gene discussed is IL6; the disease is inflammatory bowel disease.